Elsevier

Preventive Medicine

Volume 20, Issue 1, January 1991, Pages 162-169
Preventive Medicine

Organizing multicenter trials: Lessons from the cooperative oncology groups

https://doi.org/10.1016/0091-7435(91)90017-XGet rights and content

Abstract

The execution of cancer clinical therapy trials has evolved over the past 45 years and is centered in the Clinical Oncology Group mechanism. The organization, statistical and administrative support, protocol development, and quality control systems have been worked out well and can be described in detail through the Eastern Cooperative Oncology Group. Prevention trials, on the other hand, are larger and fewer and take longer to complete. They involve people who are healthy or not as motivated to take pills or change lifestyle habits as those who are ill. The problems of compliance, toxicity, and costs become major issues. The practice of medicine is organized to take care of sick people and not healthy volunteers. We describe potential roles for Clinical Oncology Groups. These include preliminary tests of prevention agents for safety and toxicity much like Phase 1 trials with cytotoxic agents. A second important possible involvement would be to provide patients at high risk for developing second cancers, treatment- or non-treatment-induced, for prevention trials. A third set of individuals that can be recruited through current group resources are relatives of cancer patients who themselves might be highly motivated to participate in prevention trials. While the Clinical Oncology Groups may not have primary roles in prevention trials, they do represent a resource that has trial discipline and willingness and could facilitate the research efforts in chemoprevention.

References (3)

  • PA Williams et al.

    Barriers and Incentives for primary-care physicians in cancer prevention and detection

    Cancer

    (1987)
There are more references available in the full text version of this article.

Cited by (0)

Presented at the Workshop on Antiestrogen Prevention of Breast Cancer, October 2–3, 1989, Madison, WI. Proceedings cosponsored by the National Cancer Institute (Grant 1 R13 CA49561-01) and the American Cancer Society (Grant RD 291).

View full text